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Background: Mechanical heart valve replacement requires lifelong antico- 
agulant treatment. Aspirin has proved useful in further reducing throm- 
boembolic events when added to oral anticoagulants. However, increased 
(gastrointestinal) bleeding was observed at the doses previously tested for 
this combination in heart valve prostheses. Methods: We performed a 
prospective randomized trial to compare the combination of low-intensity 
oral anticoagulants (international normalized ratio 2.5 to 3.5) plus aspirin 
(100 mg/day)(arm A) versus high-intensity oral anticoagulants alone (arm 
B) (international normalized ratio 3.5 to 4.5). Arm A included 258 patients 
and arm B 245 patients. The two groups were comparable for all baseline 
characteristics. Results: The outcomes of the study were embolism, valve 
thrombosis, and major hemorrhage. The median follow-up was 23 months. 
The two treatments offered similar antithrombotic protection. The inci- 
dence of embolic episodes was 1.32 per 100 patient-years (95% confidence 
interval 0.53 to 2.7) for arm A and 1.48 per 100 patient-years (95% 
confidence interval 0.59 to 3.03) for arm B. Major hemorrhage occurred in 
1.13 per 100 patient-years (95% confidence interval 0.41 to 2.45) for arm A 
and 2.33 per 100 patient-years (95% confidence interval 1.17 to 4.14) for 
arm B. Gastrointestinal bleeding was not increased by this combined 
reduced dose of aspirin and coumarin. (J Thorac Cardiovasc Surg 1997; 
113:910-6) 
T he past 20 years have witnessed dramatic im- provements in the morbidity of prosthetic heart 
valves. Lifelong oral anticoagulation is recom- 
mended to reduce the incidence of systemic embo- 
lism. However, thromboembolism still arises in up 
to 2% of patients per year. 1 Several trials tested the 
combination of an oral anticoagulant plus an anti- 
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platelet agent in patients with prosthetic valves: the 
combined therapy tended to decrease the incidence 
and severity of embolic episodes with some increase 
in bleeding, mainly in the digestive tract. 2-5 This was 
particularly true when aspirin at doses greater than 
500 rag/day was combined with high-intensity cou- 
marin. The optimal therapeutic range for any anti- 
thrombotic scheme should be consistent with ade- 
quate thromboembolic protection but as low as 
possible to avoid therapy-related bleeding. Major 
bleeding events range between 0.7% to 6.3% per 
patient_year ~, 6 and the incidence increases as the 
international normalized ratio (INR) increases] A
recent metaanalysis 8 has compared the efficacy and 
safety of combined antiplatelet plus anticoagulant 
therapy with anticoagulant monotherapy: the com- 
bined therapy significantly reduced embolism by 
67% along with a significant but undesirable 60% 
increment in hemorrhagic events. Furthermore, an 
impressive twofold increment in major gastrointes- 
tinal and other bleeding raised the question about a 
safer dose of aspirin, if any, to be combined with 
oral anticoagulants. 
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Evidence indicates that gastrointestinal symptoms 
and bleeding associated with aspirin are dose depen- 
dent.9, 10 Low doses of aspirin have demonstrated 
clear cardiovascular benefits, u and the antithrom- 
boric effects of aspirin were evident at doses greater 
than 100 mg/day. A recent rial in patients with heart 
valve disease aimed at a lower aspirin dose (100 
rag/day) while maintaining an INR between 3 and 
4.5. I2 However, the rates of bleeding showed that 
gastrointestinal and other major bleeding were still a 
problem for the aspirin group. 
The efficacy and safety of the combination of 
low-dose aspirin plus a less intense oral anticoagu- 
lation has not been tested against standard-intensity 
oral anticoagulation. We performed a prospective 
randomized trial comparing oral anticoagulation 
( INR 2.5 to 3.5) in combination with 100 rag/day of 
plain aspirin versus oral anticoagulation alone ( INR 
3.5 to 4.5). 
Methods 
This study was opened for patient accrual in July 1988 
and remained open through July 1992. The patients were 
followed up for a median of 23 months and for a maxi- 
mum of 47 months. The study was open, because the 
investigators who saw the patients during the follow-up 
needed to adjust he acenocoumarol dosage to attain the 
targeted INR. 
Patients with a mechanical prosthetic heart valve were 
randomized with a computer-generated program to arm 
A, oral anticoagulation (INR 2.5 to 3.5) plus aspirin (100 
rag/day), or arm B, oral anticoagulation alone (INR 3.5 to 
4.5). 
Patients were randomized either promptly after the 
operation (when anticoagulation was considered to be 
adequate) or at different variable intervals between the 
operation and the start of this study, switching from a 
different herapy to one of the two arms of this protocol. 
Patients with previous gastrointestinal bleeding and pa- 
tients with a previous history of embolic episodes or 
suspected hemorrhagic tendency were excluded from the 
study. 
Follow-up endpoints included thromboembolism and 
major hemorrhage. Cerebral embolism was defined as a 
sudden neurologic event (focal motor weakness, visual 
deficit, or speech disturbance) with a computed tomo- 
graphic brain scan negative for intracranial bleeding and 
for which there was no other clinical explanation. Embolic 
events were graded as to the presence or absence of any 
residual sequel, but transient ischemic events were also 
considered. Peripheral embolism was diagnosed by an- 
giography or surgery. Valve thrombosis was confirmed by 
surgery. Major hemorrhage was considered present when 
the patient died or required transfusion or hospitalization. 
All other bleeding episodes were defined as minor. 
Anticoagulation was monitored by prothrombin 
time13, 14 measured with the use of human brain throm- 
boplastin with an international sensitivity index from 1.05 
to 1.15 and a manual coagulation test. This was standard- 
ized using Argentine reference thromboplastin, 15 con- 
trolled versus international reference thromboplastin. ~6 
The prothrombin time ratio was converted into interna- 
tional normalized ratio (INR). 
All the patients enrolled in the study gave informed 
consent. Patients were repeatedly instructed to report any 
symptoms uggestive of embolism or hemorrhage. The 
percentage of anticoagulation controls within the aimed 
therapeutic range was calculated for each year of fol- 
low-up in each patient. 
Statistical methods. To test whether the proportion of 
embolism was the same in the two groups at follow-up, we 
tested for equal proportions from two independent sam- 
plesJ 7 The same was done for major hemorrhage and for 
the combined endpoint of embolism or major hemor- 
rhage. 
Time free of events was calculated from the entry date 
until the first occurrence of an embolism, a major hem- 
orrhage, or embolism and/or major hemorrhage. For each 
of the endpoints, we used the product-limit method of 
Kaplan-Meier is to plot the curve in each group on time 
free of the endpoint. The log-rank test 19 was used to test 
whether these curves were equal. 
The proportional hazards model developed by Cox, 2° 
using the maximum partial likelihood ratio statistic, was 
used to assess the joint effect of treatment and patient 
characteristics (age, sex, valve design, valve position, 
postoperative cardiac rhythm, postoperative atrial size, 
interval between the operation and admission to the 
protocol, and concomitant coronary bypass procedure) on 
each of the three outcomes: embolism, major hemor- 
rhage, and embolism and/or major hemorrhage. 
All p values are two-sided; a level of 0.05 was consid- 
ered significant. Egret (SERO, Seattle, Wash.) and Stata 
(Stata Corporation, College Station, Tex.) were used to 
perform all the statistical analyses. 
Results 
Patient characteristics. A total of 503 patients 
were randomized into the study. The baseline char- 
acteristics are shown in Table I. The two groups 
were comparable except for the higher prevalence of 
atrial fibrillation in arm A. Fifty-three (10.5%) of 
the 503 patients had concomitant surgical proce- 
dures, the most common being coronary artery 
bypass grafting in 21 (8%) patients in arm A and 13 
(5%) patients in arm B. 
The total follow-up was 529 years for arm A and 
471 years for arm B. The median follow-up was 23 
months. Thirty patients (nine from arm A, 21 from 
arm B) died. One patient (arm B) died after a 
cerebral hemorrhage. Twenty-nine deaths were un- 
related to the antithrombotic therapy. Two patients 
were withdrawn from the protocol because chronic 
renal failure developed and it was difficult to main- 
tain their anticoagulation level; 20 patients from 
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Table I. Baseline patient characteristics 
Arm A (n = 258) Arm B (n = 245) 
No. % No. % 
Median age (yr) 54 53 
Male patients 154 60 138 56 
Female patients 104 40 107 44 
Valve position 
Aortic 164 64 169 69 
Mitral 79 31 69 28 
Tricuspid 2 0.8 0 
Aortic and mitral 13 5 7 3 
Valve type 
Start-Edwards 63 24 67 27 
Disc* 169 66 158 64 
St. Jude Medical 14 5 9 4 
Unknown 12 5 11 5 
Cardiac rhythm 
Atrial fibrillation 53 20t 36 15 
Synus rhythm 150 58 152 62 
Pacemaker 2 1 5 2 
Unknown 53 21 52 21 
Associated surgical procedures 
CABG 21 75 13 52 
Mitral commissurotomy 3 11 8 32 
Others 4 14 4 16 
Interval between surgery and admission to protocol 
<6 mo 128 50 121 49 
->6 mo 130 50 124 51 
*Includes Bj6rk-Shiley (Shiley, Inc., Irvine, Calif.), Medtronic Hall (Medtronic, Inc., Minneapolis, Minn.), 
Omniscience (Medical Inc., Inver Grove Heights, Minn.). 
tp = 0.0438. 
Sorin (Sorin Biomedica Spa, Saluggio, Italy), and 
Table II. Adequacy of anticoagulation 
Arm A Arm B 
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 
Mean INR 3.05 3.18 3.1 3.78 4 4.06 
Adequate (%) 46 49 47 32 36 37 
Insufficient (%) 30 24 30 45 36 38 
Excessive (%) 24 27 23 23 28 25 
arm A (8%) and 20 patients from arm B (8%) were 
lost to follow-up. 
Adequacy of anticoagulation. The median INR 
calculated for each year of evaluation was adequate 
in both arms of the protocol (Table II). Mean INRs 
for the first 3 years of follow-up were 3.11 in arm A 
and 3.98 in arm B (p = 0.0000 for the comparison of 
each of the years). 
Thromboembolie episodes. The incidence of em- 
bolism was 2.7% (95% confidence interval [CI] 1.09 
to 5.5) for arm A and 2.8% (95% CI 1.11 to 5.7) for 
arm B. The estimated survival free of embolism at 
46 months was 94% (95% CI 0.87 to 0.97) for arm A 
and 93% (95% CI 0.84 to 0.96) for arm B (p = 
0.7008). 
In arm A there were seven thromboembolic epi- 
sodes (Table III). Total embolism rate was 2.7% or 
1.32 episodes per 100 patient-years (95% CI 0.53 to 
2.7); for cerebral episodes only, the rate was 1.9% or 
0.94 episodes per 100 patient-years (95% CI 0.30 to 
2.19). In arm B there were seven thromboembolic 
events (2.8%). One of the cerebral emboli under- 
went a hemorrhagic transformation. The annualized 
rate of embolism was of 1.48 episodes per 100 
patient-years (95% CI 0.59 to 3.03). Prothrombin 
times at the time of the embolism were available in 
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Table IIL Thromboembolic episodes 
Arm A (n = 258) Arm B (n = 245) 
No. % No. % 
Cerebral with sequelae 




Episodes per 100 patient-years 
1 14 3 43 
4 57 4 57 
1 14 
1 14 
7 2.7 7 2.8 
1.32 1.48 
(95% CI 0.53 to 2.7) (95% CI 0.59 to 3.03) 
T/A, Transient ischemic attack. 
six of the seven patients in arm A: in five of the stx 
patients (83%) the prothrombin times were within 
the therapeutic range, and in one (17%) anticoagu- 
lation was inadequate. In arm B, three of seven 
patients had prothrombin times (43%) within the 
therapeutic range, three (43%) had inadequate an- 
ticoagulation, and one (14%) had excessive antico- 
agulation. Two of the emboli n each group arose in 
patients who had atrial fibrillation. 
Position of the valve. Of the seven patients hav- 
ing embolic events in arm A, four (57%) had mitral 
prostheses and three had aortic valves (43%). In 
arm B, two (29%) of the seven patients having 
embolic episodes had mitral prostheses and five 
(71%) had aortic valves. The rate of embolism for 
mitral and aortic valves in arm A was 5.06 or 2.5 
(95% CI 0.68 to 6.28) episodes per 100 patient-years 
and 1.83 or 0.87 (95% CI 0.18 to 2.54) episodes per 
100 patient-years, respectively. In arm B the rate of 
embolism for mitral and aortic valves was 2.82 or 
1.44 (95% CI 0.17 to 5.10) episodes per 100 patient- 
years and 2.99 or 1.59 (95% CI 0.52 to 3.69) 
episodes per 100 patient-years, respectively. The 
estimated survival free of embolism at 46 months 
was 94% (95% CI 0.86 to 0.97) for mitral valves, 
93% (95% CI 0.86 to 0.93) for aortic valves, and 
100% for double prostheses (p = 0.1321). 
Type of valve. The rates of embolism were 6.34 
(95% CI 1.'75 to 15.4) and 1.56 (95% CI 0.32 to 4.49) 
(p = 0.0842) for caged-ball versus non-caged-ball 
valves for arm A and 7.67 (95% CI 2.46 to 16.66) 
and 1.13 (95% CI 0.13 to 4.04) (p = 0.0183) for arm 
B, respectively. 
Bleeding complications. The incidence of major 
bleeding was 2.32% (95% CI 0.85 to 4.99) for arm A 
and 4.49% (95% CI 2.26 to 7.89) for arm B. The 
estimated survival free of hemorrhage at 46 months 
was 97% (95% CI 0.92 to 0.99) for arm A and 91% 
(95% CI 0.84 to 0.95) for arm B (p = 0.1064). 
Table IV shows the sites of major and minor 
bleeding episodes. There were six (2.32%) major 
bleeding episodes in arm A (1.13 per 100 patient- 
years; 95% CI 0.41 to 2.45), and 11 (4.49%) in arm 
B (2.33 per 100 patient-years; 95% CI 1.17 to 4.14). 
This represents a reduction in the relative risk of 
major bleeding for the less intense anticoagulation 
arm of 52% (95% CI 0.19 to 1.38) (p = 0.2731). 
Three cerebral hemorrhages occurred in arm B and 
one was fatal. The incidence of major gastrointesti- 
nal bleeding was higher in arm B (2.45% or 1.27 per 
100 patient-years; 95% CI 0.46 to 2.75) than in arm 
A (0.77% or 0.37 per 100 patient years; 95% CI 0.04 
to 1.35). 
In arm A, a duodenal ulcer was identified as a 
predisposing factor in one of three patients with 
gastrointestinal bleeding; in one patient with gyne- 
cologic bleeding, a previous bleeding tendency was 
identified. In arm B, five of the 11 patients with 
major bleeding had possible predisposing factors: 
recent cranial trauma, lung carcinoma, vascular mal- 
formation in three patients with cerebral bleeding, 
chronic renal failure, and bacterial endocarditis in 
two patients with gastrointestinal b eeding. Even 
after the exclusion of patients with a predisposing 
cause, the rate of gastrointestinal bleeding was more 
than double in the arm with more intense anticoag- 
ulation without aspirin (Table IV). 
Four (66%) of the six patients with hemorrhagic 
complications in arm A had slightly excessive anti- 
coagulation, one (17%) had adequate anticoagula- 
tion, and the remaining patient (17%) had insuffi- 
cient anticoagulation. I  arm B, three (27%) of the 
11 with hemorrhagic omplications had excessive 
anticoagulation (one with a fatal cerebral hemor- 
rhage) and five (45%) had insufficient anticoagula- 
tion. 
Failure-free survival. Thromboembolism or ma- 
jor hemorrhage occurred in 13 patients in arm A 
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Table IV. Bleeding episodes 
Arm A (n = 258) Arm B (n = 245) 





Soft tissue hematoma 
Rate 
Episodes per 100 patient-years 
3* 27 
3 50 6 54 
3 50 1 9 
1 9 
6 2.3% 11 4.5 
1.13 2.33 
(95% CI 0.41 to 2.45) (95% CI 1.17 to 4.14) 
Minor bleeding 
Hematuria 12 34 6 15 
Epistaxis 10 28 8 19 
Gastrointestinal? 2 6 6 15 
Menorrhagia 4 11 3 7 
Ecchymoses 1 2.8 8 19 
Hemoptysis 2 5 
Gingival bleeding 2 5 
Proctorrhagia 1 2.8 5 12 
Others 5 14 1 2.4 
Rate 35 14 41 17 
*One lethal. 
?The total number of gastrointestinal hemorrhages after the exclusion of patients with a potential predisposing cause was 4 or 0.76 per 100 patient-years (95% 
CI 0.20 to 1.92) and 10 or 2.12 per 100 patient-years (95% CI 1.02 to 3.86) for arms A and B, respectively (p = 0.1425). 
(5.03% or 2.45 per 100 patient-years; 95% CI 1.31 to 
4.16) and 18 patients in arm B (7.34% or 3.82 per 
100 patient-years; 95% CI 2.28 to 5.97). The actu- 
arial risk of embolism and major bleeding at 40 
months (Fig. 1) was 10% for arm A and 15% for arm 
B (p = 0.1576). This represents a relative risk 
reduction of 69% (95% CI 0.34 to 1.37) (p = 
0.3732). 
Cox multivariate analysis. Several Cox models 
were performed, using treatment and the set of 
patient characteristics at diagnosis, that will lead to 
an adjusted effect of treatment on outcomes. 
One set of models was developed for embolism, in 
which the presence of postoperative atrial size (>50 
mm) was a statistically significant predictor of em- 
bolism. 
Finally, a Cox model was developed for the joint 
effect of embolism and major hemorrhage, in which 
postoperative atrial size was the only significant 
predictor of events. 
Discussion 
In this randomized trial, we demonstrated that 
the addition of 100 mg daily aspirin to a less intense 
oral anticoagulation program offered the same an- 
tithrombotic protection and did not increase the risk 
of bleeding than a more intense anticoagulant-alone 
regimen. Moreover, a better quality of life (event- 
free survival) and a tendency toward fewer and 
milder episodes of cerebral embolism were offered 
by the combined treatment. Although embolism was 
more prevalent in caged-ball valves in both groups, 
the difference reached statistical significance only in 
the anticoagulant-alone group. 
When this trial was designed, the currently sug- 
gested practice for patients with prosthetic heart 
valves was to prolong the INR from 3.0 to 4.5. 21 The 
last consensus on oral anticoagulation a2 suggested a 
lower INR of 2.5 to 3.5 for patients with non-caged- 
ball prostheses. This recommendation was substan- 
tiated in a literature review. 23 However, there are no 
randomized clinical trials comparing the old (3 to 
4.5) versus the newer (2.5 to 3.5) recommended 
intensities. Moreover, a substantial number of pa- 
tients with old, more thrombogenic prostheses still 
attend the anticoagulation clinics. Whether the 
same level of anticoagulation is required when cou- 
marin is combined with a platelet inhibitor is un- 
known. The addition of aspirin to oral anticoagula- 
tion showed a significative reduction in the rate of 
thromboembolism. 2'3 However, the incidence of 
gastrointestinal bleeding was increased when aspirin 
was given at dosages of 1 gm/day 2 or 250 mg twice 
daily) Despite the excessive bleeding, the thrombo- 
embolic protection was sometimes poor. 4 In a recent 
study by Altman and associates, 5 lower intensity 
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Fig. 1. Efficacy and safety. Cumulative risk of events (embolism and/or major hemorrhage) attributable to
antithrombotic herapy. 
anticoagulation was as effective as and safer than a 
higher intensity regimen, at least when combined with 
two platelet inhibitors. The lack of a control group 
treated with warfarin alone and the fact that most of 
the hemorrhages occurred within the targeted level of 
anticoagulation raises the question about the minimal 
(but still effective) dosage Of aspirin. 
If the deleterious effect of aspirin is a function of 
the dose, 9 one can speculate whether a lower dose 
could retain efficacy while reducing the bleeding. 
Recently, low-dose aspirin has proven successful in 
lowering cardiac and cerebral vascular events. Tur- 
pie and coworkers 12 found that 100 mg aspirin 
added to warfarin (INR 3 to 4.5) reduced signifi- 
cantly the embolic rates, when compared with a 
warfarin-alone regimen of similar intensity. How- 
ever, the mean INRs for both aspirin and placebo 
groups were similarly low (3.1 and 3), and 49% of 
the INR measurements fell below the targeted level. 
Thus it might be feasible that such low levels of 
anticoagulation were not optimum to prevent em- 
bolism in the warfarin-alone group, raising uncer- 
tainties about the performance of the combined 
therapy if tested against a more intense, better 
performing anticoagulant-alone regimen. The safety 
of the association might be questioned, because 
more total, major, and gastrointestinal hemorrhages 
occurred among patients treated with warfarin plus 
aspirin. 12 A recent metaanalysis that confirmed the 
benefits of adding aspirin to coumarin in further 
reducing thromboembolism revealed an impressive 
increment in iatrogenic bleeding, which makes un- 
acceptable the combination of doses of aspirin 
greater than 100 mg or intensities greater than INR 
3.5. 8 Recent trials aimed at a less intense anticoag- 
ulant schedule: INR below 3.5. 24,25 An adequate 
embolism protection and a reduced risk of hemor- 
rhagic complications was found. Unfortunately, 
these trials did not include standard (intense) anti- 
coagulation or combined anticoagulant-plus-aspirin 
groups. Moreover, in Turpie's trial the warfarin- 
alone arm (mean INR 3.1) showed a higher (4.6 per 
100 patient-years) incidence of embolism. Hence 
evidence about the antithrombotic efficacy of low- 
intensity anticoagulation alone is conflicting, and it 
is not Clear whether esults from these less intense 
regimens can be improved by adding aspirin or 
other antiplatelet agents. 
In our study we had a low incidence of systemic 
embolism in both arms (1.32 and 1.48 per 100 patient- 
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years). Most of our episodes were cerebral (five of 
seven in arm A and seven of seven in arm B) and left 
no neurologic deficit in four of five and four of seven 
patients. Despite the similarly low incidence of embo- 
lism, the aspirin arm showed a tendency to more 
benign (transient) cerebral episodes. Furthermore, 
patients having caged-ball valves benefited from the 
combined therapy. This benefit was not counterbal- 
anced by an increase in bleeding: we found the rate of 
major bleeding episodes in the less intense arm (1.13 
and 2.33 per 100 patient-years, respectively) dropped 
by more than half. Gastrointestinal bleeding was not 
increased by the addition of aspirin. 
Our results indicate that the addition of low-dose 
aspirin to a low-intensity oral anticoagulant regimen 
in this selected population free from gastrointestinal 
hemorrhage or hemorrhagic history conferred anti- 
thrombotic protection as effectively as the high- 
intensity "standard" anticoagulation without in- 
creasing the likelihood of major hemorrhages. The 
effects were not limited to any particular subgroup 
of patients with mechanical valves. Further trials 
seem warranted, looking for special subgroups (el- 
derly patients or those with coronary or cerebrovas- 
cular disease) that could be particularly benefited by 
the combination therapy. 
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